Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors for Cancer Treatment
Summary
USPTO published patent application US20260097019A1 disclosing trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors for treating cancer and inhibiting tumor growth and metastasis. Inventors: Kavitha Nellore and Subramanya Hosahalli. Application filed April 30, 2025.
What changed
USPTO published patent application US20260097019A1 disclosing novel methods of using trisubstituted benzotriazole derivatives to inhibit dihydroorotate oxygenase enzymes in cancer cells, thereby treating cancer and inhibiting tumor growth and metastasis. The application covers compounds with substituents R1, R2, and R3 as defined in the specification, and pharmaceutical salts thereof.
Affected parties including pharmaceutical companies, biotech firms, and cancer drug developers should monitor this application for potential future patent rights that may affect R&D activities in the dihydroorotate oxidase inhibitor space. Competitors developing similar enzyme inhibitors for oncology applications should review the claim scope to assess potential freedom-to-operate implications.
What to do next
- Monitor for updates on patent prosecution status
- Review application claims for potential competitive impact
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS
Application US20260097019A1 Kind: A1 Apr 09, 2026
Inventors
Kavitha Nellore, Subramanya Hosahalli
Abstract
The present invention provides methods for treating a cancer in a subject and for inhibiting tumor growth, metastasis or a dihydrorotate oxygenase enzyme activity of a tumor or cancer cell. At least one trisubstituted benzotriazole derivative with the formula (I) is administered to the subject or is contacted with the cancer cell. Compounds of formula (I) have substituents R1, R2 and R3 which have the meanings given in the specification, and pharmaceutically acceptable salts thereof.
CPC Classifications
A61K 31/4192 A61K 31/454 A61K 31/496 A61K 31/5377 A61P 35/02
Filing Date
2025-04-30
Application No.
19195209
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.